Abstract:Fecal microbiota transplantation (FMT) and short‐chain fatty acids (SCFAs) replenishment exerted anti‐neuroinflammatory effects through switching microglial phenotype from M1 toward M2. Furthermore, FMT and SCFAs treatment alleviated neuronal loss and microglia‐mediated synaptic loss and maintained the normal process of synaptic vesicle fusion and release, resulting in the improvement of synaptic plasticity. In addition, FMT and SCFAs supplement prevented oxidative phosphorylation dysfunction via mitochondrial metabolic reprogramming. Aims Clear roles and mechanisms in explaining gut microbial dysbiosis and microbial metabolites short‐chain fatty acids (SCFAs) alterations in chronic cerebral ischemic pathogenesis have yet to be explored. In this study, we investigated chronic cerebral hypoperfusion (CCH)‐induced gut microbiota and metabolic profiles of SCFAs as well as the effects and mechanisms of fecal microbiota transplantation (FMT) and SCFAs treatment on CCH‐induced hippocampal neuronal injury. Methods Bilateral common carotid artery occlusion (BCCAo) was used to establish the CCH model. Gut microbiota and SCFAs profiles in feces and hippocampus were evaluated by 16S ribosomal RNA sequencing and gas chromatography–mass spectrometry. RNA sequencing analysis was performed in hippocampal tissues. The potential molecular pathways and differential genes were verified through western blot, immunoprecipitation, immunofluorescence, and ELISA. Cognitive function was assessed via the Morris water maze test. Ultrastructures of mitochondria and synapses were tested through a transmission electron microscope. Results Chronic cerebral hypoperfusion induced decreased fecal acetic and propionic acid and reduced hippocampal acetic acid, which were reversed after FMT and SCFAs administration by changing fecal microbial community structure and compositions. Furthermore, in the hippocampus, FMT and SCFAs replenishment exerted anti‐neuroinflammatory effects through inhibiting microglial and astrocytic activation as well as switching microglial phenotype from M1 toward M2. Moreover, FMT and SCFAs treatment alleviated neuronal loss and microglia‐mediated synaptic loss and maintained the normal process of synaptic vesicle fusion and release, resulting in the improvement of synaptic plasticity. In addition, FMT and SCFAs supplement prevented oxidative phosphorylation dysfunction via mitochondrial metabolic reprogramming. The above effects of FMT and SCFAs treatment led to the inhibition of CCH‐induced cognitive impairment. Conclusion Our findings highlight FMT and SCFAs replenishment would be the feasible gut microbiota‐based strategy to mitigate chronic cerebral ischemia‐induced neuronal injury.

The Bridge Between Ischemic Stroke and Gut Microbes: Short-Chain Fatty Acids

Gut Microbiota-Mediated Ursodeoxycholic Acids Regulate the Inflammation of Microglia Through TGR5 Signaling after MCAO.

Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack.

Crosstalk between the Gut and Brain in Ischemic Stroke: Mechanistic Insights and Therapeutic Options

Therapeutic approaches targeting the gut microbiota in ischemic stroke: current advances and future directions

Short-chain fatty acid on blood-brain barrier and glial function in ischemic stroke

Role of the gut microbiota in complications after ischemic stroke

From Gut to Brain: Unraveling the Intricate Link Between Microbiome and Stroke

Short‐chain fatty acids: bridges between diet, gut microbiota, and health

The gastrointestinal-brain-microbiota axis: a promising therapeutic target for ischemic stroke

Gut Microbiota in Ischemic Stroke: Role of Gut Bacteria-Derived Metabolites

The role of gut microorganisms and metabolites in intracerebral hemorrhagic stroke: a comprehensive review

Aberrant Branched‐chain Amino Acid Accumulation along the Microbiota–gut–brain Axis: Crucial Targets Affecting the Occurrence and Treatment of Ischaemic Stroke

Could the Gut Microbiota Serve as a Therapeutic Target in Ischemic Stroke?

Gut Microbiota and Their Metabolites in Stroke: A Double-Edged Sword

Role of the Gut Microbiota in Stroke Pathogenesis and Potential Therapeutic Implications

Influence of the brain‐gut axis on neuroinflammation in cerebral ischemia‐reperfusion injury (Review)

Role of Gut Microbiota in Ischemic Stroke: A Narrative Review of Human and Animal Studies

Bioinformatics Approach to Identify the Pathogenetic Link of Gut Microbiota-Derived Short-Chain Fatty Acids and Ischemic Stroke

Gut-brain axis: Focus on gut metabolites short-chain fatty acids

Fecal microbiota transplantation and short‐chain fatty acids protected against cognitive dysfunction in a rat model of chronic cerebral hypoperfusion